⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

June 1, 2007Clinical Cancer Research

Identification ofNTN4, TRA1, andSTC2as Prognostic Markers in Breast Cancer in a Screen for Signal Sequence Encoding Proteins

Selma Esseghir Alan Kennedy Pooja Seedhar Ashutosh Nerurkar Richard Poulsom Jorge S. Reis‐Filho Clare M. Isacke

View at Publisher

Ask AI

Bookmark

Share

Abstract

This article describes the identification of three secreted proteins, NTN4, TRA1, and STC2, as potential novel prognostic markers in breast cancer.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Esseghir et al. (2007) studied this question.

synapsesocial.com/papers/69d69424e76a53de2732f6c6 https://doi.org/10.1158/1078-0432.ccr-07-0224

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Identification of transmembrane proteins as potential prognostic markers and therapeutic targets in breast cancer by a screen for signal sequence encoding transcriptsPrognostic Study · 2006 · 74 citations
2pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐upOriginal Research · 1991 · 6,179 citations
3Breast Cancer Staging: Working With the Sixth Edition of the AJCC Cancer Staging ManualPrognostic Study · 2006 · 391 citations
4The I.M.A.G.E. Consortium: An Integrated Molecular Analysis of Genomes and Their ExpressionOriginal Research · 1996 · 1,123 citations
5Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast CarcinomaOriginal Research · 2004 · 2,663 citations

More related papers

Molecular Profiling of Inflammatory Breast Cancer2004
Identification of interleukin‐8 as estrogen receptor‐regulated factor involved in breast cancer invasion and angiogenesis by protein arrays2004
Tissue-Wide Expression Profiling Using cDNA Subtraction and Microarrays to Identify Tumor-Specific Genes2004

More from Clinical Cancer Research

Serial circulating tumour DNA monitoring in first-line advanced NSCLC (COPE): a randomized, two-arm non-comparative phase II trialWed,
DuoBody®-FAPαxDR4 is a novel DR4 agonist that induces potent antitumor activity through FAPα-dependent, DR4-transactivation-mediated apoptosisWed,